{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
iTeos Therapeutics, Inc.
Is iTeos Therapeutics, Inc. overvalued or undervalued?
As of August 8, 2024, iTeos Therapeutics, Inc. is rated as "risky" and overvalued, with key financial metrics indicating distress, including a troubling -23.22% ROE and a 1-month return of 18.11%, despite a 31.69% decline over the past year.
Is iTeos Therapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend has shifted to mildly bearish, influenced by daily moving averages, while weekly indicators show mixed signals, leading to overall uncertainty.
Who are in the management team of iTeos Therapeutics, Inc.?
As of March 2022, the management team of iTeos Therapeutics, Inc. includes Mr. David Hallal (Independent Chairman), Dr. Michel Detheux (CEO), and several Independent Directors: Dr. Priyanka Belawat, Dr. Detlev Biniszkiewicz, Mr. Aaron Davis, Dr. Derek DiRocco, and Ms. Ann Rhoads. They are responsible for the company's strategic direction and operations.
What does iTeos Therapeutics, Inc. do?
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics. It has a market cap of $383.50 million and reported a net profit loss of $35 million as of March 2025.
How big is iTeos Therapeutics, Inc.?
As of Jun 18, iTeos Therapeutics, Inc. has a market capitalization of 383.50 million, with net sales of 35.00 million and a net profit of -130.81 million over the latest four quarters. Shareholder's funds are reported at 590.29 million, and total assets amount to 686.98 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
